Meeting
2013 ASCO Annual Meeting
Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy.
Authors
Carlo Gambacorti-Passerini
University of Milan-Bicocca, Monza, Italy
Carlo Gambacorti-Passerini , Tim H. Brummendorf , Jorge E. Cortes , Jeffrey H. Lipton , Dong-Wook Kim , Eric Leip , Kathleen Wyant Turnbull , Hagop M. Kantarjian , Hanna Jean Khoury
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00261846
Citation
J Clin Oncol 31, 2013 (suppl; abstr 7099)
DOI
10.1200/jco.2013.31.15_suppl.7099
Abstract #
7099
Poster Bd #
42C
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.
First Author: Carlo Gambacorti-Passerini
Poster
2012 ASCO Annual Meeting
Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome–positive (Ph+) leukemia in older versus younger patients (pts).
First Author: Tim H. Brummendorf
Poster
2023 ASCO Annual Meeting
Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.
First Author: Tony Varughese
Poster
2014 ASCO Annual Meeting
Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
First Author: Belal Firwana